Scholarlink

Background <p>Post-translational modifications (PTMs) are key epigenetic regulators modulating glioma initiation, progression, and therapeutic response by regulating target proteins’ properties. Major PTM subtypes (phosphorylation, ubiquitination, SUMOylation, acetylation, succinylation, lactylation, glycosylation, and methylation) have context-dependent roles; their dysregulation disrupts homeostasis, promoting oncogene activation, stemness, and TMZ resistance. However, PTM cross-regulation, redundancy, and clinical translation remain unclear.</p> Methods <p>This review adopts a comprehensive perspective to summarize advances on PTM dysregulations in gliomas. It synthesizes findings on the regulatory roles of each major PTM subtype in glioma pathophysiology, their functional impacts on glioma biological processes, and the implications of PTM dysregulation in therapeutic resistance.</p> Results <p>Phosphorylation drives critical cell signaling transduction, like mTOR and EGFR signaling cascades. Ubiquitination regulates the stability of key oncoproteins, and SUMOylation regulates nuclear processes and protein localization. Acetylation, succinylation, and lactylation are metabolite-dependent PTMs, which are closely coupled to glioma metabolic reprogramming. Histone methylation dynamically remodels chromatin accessibility to regulate gene transcription, while non-histone methylation bridges cellular signaling with epigenetic regulation. Glycosylation enhances tumor cell adhesion and invasiveness. Notably, dysregulation of these PTMs is consistently associated with glioma progression and TMZ resistance, yet the cross-regulatory networks and functional redundancy among these PTMs remain understudied.</p> Conclusions <p>This review systematically integrates current understanding of PTM dysregulation in gliomas and highlights their coordinated regulatory roles. Also, we identify unresolved gaps in PTM crosstalk and clinical translation and provide a foundation for developing PTM-targeted precision therapies.</p> Clinical trait number <p>Not applicable.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dysregulation of post-translational modifications in glioma: advances in pathological mechanisms and clinical targeting strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月6日

查看全文
  • Jiasheng Wu,
  • Hongbin Liu,
  • Xinbo Li,
  • Haohao Huang,
  • Hongtao Zhu,
  • Junwen Wang,
  • Huipeng Yue,
  • Ran Li,
  • Kai Shu,
  • Chao You

摘要

Background

Post-translational modifications (PTMs) are key epigenetic regulators modulating glioma initiation, progression, and therapeutic response by regulating target proteins’ properties. Major PTM subtypes (phosphorylation, ubiquitination, SUMOylation, acetylation, succinylation, lactylation, glycosylation, and methylation) have context-dependent roles; their dysregulation disrupts homeostasis, promoting oncogene activation, stemness, and TMZ resistance. However, PTM cross-regulation, redundancy, and clinical translation remain unclear.

Methods

This review adopts a comprehensive perspective to summarize advances on PTM dysregulations in gliomas. It synthesizes findings on the regulatory roles of each major PTM subtype in glioma pathophysiology, their functional impacts on glioma biological processes, and the implications of PTM dysregulation in therapeutic resistance.

Results

Phosphorylation drives critical cell signaling transduction, like mTOR and EGFR signaling cascades. Ubiquitination regulates the stability of key oncoproteins, and SUMOylation regulates nuclear processes and protein localization. Acetylation, succinylation, and lactylation are metabolite-dependent PTMs, which are closely coupled to glioma metabolic reprogramming. Histone methylation dynamically remodels chromatin accessibility to regulate gene transcription, while non-histone methylation bridges cellular signaling with epigenetic regulation. Glycosylation enhances tumor cell adhesion and invasiveness. Notably, dysregulation of these PTMs is consistently associated with glioma progression and TMZ resistance, yet the cross-regulatory networks and functional redundancy among these PTMs remain understudied.

Conclusions

This review systematically integrates current understanding of PTM dysregulation in gliomas and highlights their coordinated regulatory roles. Also, we identify unresolved gaps in PTM crosstalk and clinical translation and provide a foundation for developing PTM-targeted precision therapies.

Clinical trait number

Not applicable.

Graphical Abstract